Professional Summary
Professional Overview
David Butler is a seasoned biotechnology executive with extensive experience in strategic leadership, drug development, and scientific innovation. As the Chief Technology Officer at Hongene Biotech Corporation, he oversees the company's technology roadmap, guides research and development initiatives, and drives the implementation of cutting-edge solutions to address complex challenges in the life sciences industry.
Experience Summary
Current Role
As the Chief Technology Officer at Hongene Biotech Corporation, David is responsible for spearheading the company's technology strategy and ensuring the seamless integration of innovative technologies to support the development of novel therapeutics. He plays a pivotal role in aligning Hongene's technological capabilities with its business objectives, fostering cross-functional collaboration, and driving the implementation of transformative solutions.
In addition to his role at Hongene, David serves as a Member of the Board of Directors at Akte Therapeutics, where he provides strategic guidance and oversight to support the company's growth. He also serves as an Entrepreneur in Residence at Yale Ventures, where he leverages his expertise to mentor and advise early-stage startups on technology and product development.
Career Progression
Prior to joining Hongene, David held several senior leadership positions in the biotechnology industry. As the Vice President, Head of Chemistry at Korro Bio, Inc., he led the company's medicinal chemistry efforts and contributed to the advancement of its pipeline of RNA-targeted therapeutics. Before that, he served as the Vice President, Head of Therapeutic Development at Alltrna, where he spearheaded the development of novel RNA-based therapies.
Earlier in his career, David held progressive roles at Wave Life Sciences, including Vice President, Head of Medicinal Chemistry and Senior Director. He also gained valuable experience as a Principal Scientist at Ontorii Inc. and Alnylam Pharmaceuticals, as well as a Senior Scientist at Organix Inc.
Academic Background
David holds a Ph.D. in Organic Chemistry from the University of Ottawa, where he conducted postdoctoral research at the university and later at Cardiff University and Queen Mary, University of London.
Areas of Expertise
- Strategic technology planning and implementation
- Drug discovery and development
- Medicinal and organic chemistry
- Therapeutic RNA-based technologies
- Cutting-edge scientific research and innovation
- Cross-functional team leadership and collaboration
Professional Impact
Throughout his career, David has made significant contributions to the advancement of RNA-targeted therapeutics and the development of novel drug candidates. His expertise in medicinal chemistry and therapeutic development has led to the successful progression of several drug candidates through various stages of the pipeline. David's ability to bridge the gap between scientific research and business strategy has been instrumental in driving the growth and success of the companies he has worked with.
Conclusion
With his extensive experience, technical expertise, and strategic vision, David Butler is a valuable asset to the biotechnology industry. As the Chief Technology Officer at Hongene Biotech Corporation, he is poised to lead the company's technological transformation and contribute to the development of innovative solutions that have the potential to revolutionize the field of life sciences.
